Boehringer Ingelheim: Privacy Has its Virtues
Boehringer Ingelheim has beaten market growth for the past nine years and may continue to outperform rivals. Part of the secret: its private status affords the group a long-term outlook that's far trickier for its public peers to embrace.
You may also be interested in...
Eli Lilly & Co., on the precipice of one of the steepest patent cliffs in the industry, announced a diabetes collaboration with Boehringer Ingehheim GmbH Jan. 11 that will recharge the company's diabetes pipeline but may leave investors longing for bigger M&A action.
Regulators accept bleeding risk for superiority over warfarin, staying away from a temptingly safer but less effective dabigatran dose.
As part of its ongoing effort to develop drugs for metabolic disease, Boehringer Ingelheim is gearing up for a filing within the next few months of its first diabetes drug - the DPP-4 inhibitor linagliptin